Sign in
Taking people in South KoreaNo phase

Olmetec and nighttime blood pressure in Korean adults with mild high blood pressure

Follows adults with high blood pressure taking Olmetec to see nighttime blood pressure changes.

Key facts

Who runs it
Daewoong Pharmaceutical Co. LTD.
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension
Status
Recruiting
People taking part
12,000 people, planned
Started
17 Sept 2025
Expected to end
31 Jan 2027
Type of study
Observational
Record updated
7 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage 1 hypertension who are newly prescribed Olmetec or Olmetec Plus in routine care. They will be followed to see how their blood pressure, including at night, changes.

Age
19 years or older
Sex
All sexes can join
Disease stage
Stage 1 hypertension, diagnosed according to clinical guidelines
Earlier treatment
Newly prescribed Olmetec or Olmetec Plus in routine clinical practice

Main reasons for not taking part

  • Secondary hypertension
  • Severe hypertension that needs immediate drug treatment
  • Known allergy to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
  • Pregnant, planning to become pregnant, or breastfeeding
  • Severe kidney or severe liver problems

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults aged ≥19 years
  • Patients diagnosed with stage 1 hypertension according to clinical guidelines
  • Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
  • Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
  • Patients who voluntarily agree to participate and provide written informed consent

Who cannot take part

  • Patients with secondary hypertension
  • Patients with severe hypertension requiring immediate pharmacological i-ntervention
  • Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
  • Patients with severe renal impairment or severe hepatic impairment
  • Patients who are pregnant, planning to become pregnant, or breastfeeding
  • Patients who are unable to comply with study procedures, including ABPM
  • Patients who are deemed inappropriate for participation by the investigator

Where in South Korea

  • Multiple centers in Republic of KoreaSeoul, South KoreaContact: Yun Jeong KongTaking people

About the trial

What the trial wants to find out

This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.

The group in the trial

  • Olmetec-Based Treatment Cohort

    Patients with stage 1 hypertension who are prescribed Olmetec® or Olmetec Plus® as part of routine clinical practice will be included. Patients will be followed prospectively to assess changes in nocturnal blood pressure and blood pressure variability using ambulatory blood pressure monitoring (ABPM). No intervention beyond standard clinical care will be applied.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy of OLMETEC Tab. (or OLMETEC Plus Tab.) on Nocturnal Blood Pressure Control in Korean Patients With Stage Ⅰ Hypertension
Plain-language title
Olmetec and nighttime blood pressure in Korean adults with mild high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 April 2026